Top

Diagnostic Pathology

Published in:

Open Access 01-12-2015 | Research

Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer

Authors: Liang-liang Dong, Li-ming Chen, Wei-min Wang, Liang-ming Zhang

Published in: Diagnostic Pathology | Issue 1/2015

Abstract

Background

MicroRNA-124 (miR-124) has been reported to be downregulated in breast cancer. However, its clinical significance and prognostic value in breast cancer have not been extensively studied.

Methods

The tissue expression levels of miR-124 were measured using quantitative real-time PCR in 133 breast cancer patients. The correlation between the miR-124 levels and the clinicopathological factors of the patients was also analyzed. Survival and Cox proportional-hazards regression analyses were performed to determine the correlation between miR-124 expression levels and prognosis in the patients.

Results

Quantitative real-time PCR analysis showed that miR-124 had lower expression in breast cancer specimens than that in matched adjacent normal breast tissues (0.39 ± 0.16 vs. 1.00 ± 0.39; P < 0.05). Low miR-124 expression level was significantly associated with advanced TNM stage (P = 0.011), lymph node metastasis (P = 0.012), and poorer pathological differentiation (P = 0.023). A significant difference was found that breast cancer patients with low miR-124 expression level had distinctly shorter overall survival than patients with high miR-124 expression level (63.8% vs. 35.2%, P = 0.03). Furthermore, multivariate analysis of the prognosis factors with a Cox proportional hazards model confirmed that low miR-124 expression was a significant independent predictor of poor survival in breast cancer (HR = 3.16, 95% CI: 1.79-9.13, P = 0.017).

Conclusion

These findings proved that the decreased expression of miR-124 might be associated with tumor progression and poor prognosis in patients with breast cancer.

Virtual Slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/3752603721493544

Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36.CrossRefPubMed

Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33.CrossRefPubMedCentralPubMed

Li LC. The multifaceted small RNAs. RNA Biol. 2008;5(2):61–4.CrossRefPubMed

Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. Jama. 2008;299(4):425–36.CrossRefPubMedCentralPubMed

Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008;13(1):48–57.CrossRefPubMed

Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, Tavolaro S, et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood. 2007;109(11):4944–51.CrossRefPubMed

Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065–70.CrossRefPubMed

Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 2005;334(4):1351–8.CrossRefPubMed

Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 2007;8(10):R214.CrossRefPubMedCentralPubMed

10.

Lee MR, Kim JS. Kim KS: miR-124a is important for migratory cell fate transition during gastrulation of human embryonic stem cells. Stem Cells. 2010;28(9):1550–9.CrossRefPubMed

11.

Cheng LC, Pastrana E, Tavazoie M, Doetsch F. miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nat Neurosci. 2009;12(4):399–408.CrossRefPubMedCentralPubMed

12.

Han ZB, Yang Z, Chi Y, Zhang L, Wang Y, Ji Y, et al. MicroRNA-124 suppresses breast cancer cell growth and motility by targeting CD151. Cell Physiol Biochem. 2013;31(6):823–32.CrossRefPubMed

13.

Wang P, Chen L, Zhang J, Chen H, Fan J, Wang K, et al. Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene. 2014;33(4):514–24.CrossRefPubMed

14.

Shi XB, Xue L, Ma AH, Tepper CG, Gandour-Edwards R, Kung HJ, et al. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene. 2013;32(35):4130–8.CrossRefPubMedCentralPubMed

15.

Xia J, Wu Z, Yu C, He W, Zheng H, He Y, et al. miR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. J Pathol. 2012;227(4):470–80.CrossRefPubMed

16.

Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, Chen SP, et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut. 2012;61(2):278–89.CrossRefPubMed

17.

Li L, Luo J, Wang B, Wang D, Xie X, Yuan L, et al. Microrna-124 targets flotillin-1 to regulate proliferation and migration in breast cancer. Mol Cancer. 2013;12:163.CrossRefPubMedCentralPubMed

18.

Profumo V, Gandellini P. MicroRNAs: cobblestones on the road to cancer metastasis. Crit Rev Oncog. 2013;18(4):341–55.CrossRefPubMed

19.

Landskroner-Eiger S, Moneke I, Sessa WC. miRNAs as modulators of angiogenesis. Cold Spring Harb Perspect Med. 2013;3(2):a006643.CrossRefPubMedCentralPubMed

20.

Carleton M, Cleary MA, Linsley PS. MicroRNAs and cell cycle regulation. Cell Cycle. 2007;6(17):2127–32.CrossRefPubMed

21.

Wang S, Li H, Wang J, Wang D. Expression of microRNA-497 and its prognostic significance in human breast cancer. Diagn Pathol. 2013;8:172.CrossRefPubMedCentralPubMed

22.

Svoboda M, Sana J, Redova M, Navratil J, Palacova M, Fabian P, et al. MiR-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn Pathol. 2012;7:31.CrossRefPubMedCentralPubMed

23.

Li W, Zang W, Liu P, Wang Y, Du Y, Chen X, et al. MicroRNA-124 inhibits cellular proliferation and invasion by targeting Ets-1 in breast cancer. Tumour Biol. 2014;35(11):10897–904.CrossRefPubMed

Title: Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer
Authors: Liang-liang Dong
Li-ming Chen
Wei-min Wang
Liang-ming Zhang
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Diagnostic Pathology / Issue 1/2015
Electronic ISSN: 1746-1596
DOI: https://doi.org/10.1186/s13000-015-0257-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer

Abstract

Background

Methods

Results

Conclusion

Virtual Slides

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Virtual Slides

Please log in to get access to this content

Other articles of this Issue 1/2015

Renal carcinoid tumor with liver metastasis followed up postoperatively for 9 years

A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma

Overexpression of Trps1 contributes to tumor angiogenesis and poor prognosis of human osteosarcoma

Exuberant squamous metaplasia of the gastric mucosa in a patient with gastric adenocarcinoma

Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?

Combination of serum RASSF1A methylation and AFP is a promising non-invasive biomarker for HCC patient with chronic HBV infection